Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLD NASDAQ:CNTB NASDAQ:EXOZ NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.97M-1.2273,996 shs96,520 shsCNTBConnect Biopharma$1.56-4.3%$1.86$0.51▼$2.86$90.83M-0.09149,569 shs177,038 shsEXOZeXoZymes$12.40$10.10$8.50▼$23.99$104.00MN/A2,360 shs3,371 shsKALAKALA BIO$18.62+9.5%$8.87$2.92▼$18.89$119.36M-1.81239,104 shs548,207 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLDBoundless Bio-0.60%+1.13%+4.30%+9.72%-62.12%CNTBConnect Biopharma-7.39%-8.43%-28.19%+71.58%+29.37%EXOZeXoZymes0.00%+17.31%+23.63%-3.20%+1,239,999,900.00%KALAKALA BIO+11.33%+17.00%+128.49%+295.35%+182.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.97M-1.2273,996 shs96,520 shsCNTBConnect Biopharma$1.56-4.3%$1.86$0.51▼$2.86$90.83M-0.09149,569 shs177,038 shsEXOZeXoZymes$12.40$10.10$8.50▼$23.99$104.00MN/A2,360 shs3,371 shsKALAKALA BIO$18.62+9.5%$8.87$2.92▼$18.89$119.36M-1.81239,104 shs548,207 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLDBoundless Bio-0.60%+1.13%+4.30%+9.72%-62.12%CNTBConnect Biopharma-7.39%-8.43%-28.19%+71.58%+29.37%EXOZeXoZymes0.00%+17.31%+23.63%-3.20%+1,239,999,900.00%KALAKALA BIO+11.33%+17.00%+128.49%+295.35%+182.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLDBoundless Bio 2.25Hold$3.50207.02% UpsideCNTBConnect Biopharma 3.50Strong Buy$7.00348.72% UpsideEXOZeXoZymes 0.00N/AN/AN/AKALAKALA BIO 3.20Buy$21.7516.81% UpsideCurrent Analyst Ratings BreakdownLatest BOLD, KALA, EXOZ, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $33.009/8/2025KALAKALA BIOMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.009/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/11/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/ACNTBConnect Biopharma$26.03M3.34N/AN/A$1.67 per share0.93EXOZeXoZymes$70K1,486.23N/AN/A$1.25 per share9.92KALAKALA BIO$3.89M33.60N/AN/A$2.02 per share9.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLDBoundless Bio-$65.36MN/A0.00N/AN/AN/A-44.79%-34.24%N/ACNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AEXOZeXoZymes-$5.86MN/A0.00∞N/AN/A-134.50%-81.63%N/AKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)Latest BOLD, KALA, EXOZ, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLDBoundless BioN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLDBoundless Bio0.3914.0814.08CNTBConnect Biopharma0.017.247.24EXOZeXoZymes0.016.196.19KALAKALA BIO3.192.102.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLDBoundless BioN/ACNTBConnect Biopharma58.72%EXOZeXoZymesN/AKALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipBOLDBoundless Bio21.10%CNTBConnect Biopharma22.60%EXOZeXoZymes72.41%KALAKALA BIO8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLDBoundless Bio20722.39 million17.66 millionNo DataCNTBConnect Biopharma11055.72 million43.13 millionOptionableEXOZeXoZymes298.39 million2.31 millionN/AKALAKALA BIO307.02 million6.44 millionNot OptionableBOLD, KALA, EXOZ, and CNTB HeadlinesRecent News About These CompaniesKALA BIO (NASDAQ:KALA) Price Target Raised to $33.00 at OppenheimerSeptember 12 at 2:49 AM | americanbankingnews.comAnalysts Set KALA BIO, Inc. (NASDAQ:KALA) Price Target at $17.25September 11 at 2:19 AM | americanbankingnews.comKALA BIO (NASDAQ:KALA) Now Covered by MizuhoSeptember 10 at 8:59 AM | marketbeat.comKALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of "Buy" by AnalystsSeptember 10 at 8:23 AM | marketbeat.comMizuho Initiates Coverage of KALA BIO (KALA) with Outperform RecommendationSeptember 9 at 5:27 PM | msn.comQ3 Earnings Forecast for KALA BIO Issued By Lifesci CapitalSeptember 7, 2025 | marketbeat.comKALA BIO, Inc.'s (NASDAQ:KALA) market cap surged US$28m last week, retail investors who have a lot riding on the company were rewardedSeptember 6, 2025 | finance.yahoo.comKALA BIO (NASDAQ:KALA) Upgraded by Lifesci Capital to Strong-Buy RatingSeptember 6, 2025 | marketbeat.comKALA BIO (NASDAQ:KALA) Raised to Strong-Buy at Lifesci CapitalSeptember 5, 2025 | americanbankingnews.comADAR1 Capital Management LLC Buys 78,582 Shares of KALA BIO, Inc. $KALASeptember 4, 2025 | marketbeat.comKALA BIO (NASDAQ:KALA) Trading Up 5.9% - Time to Buy?September 3, 2025 | marketbeat.comKALA BIO to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comHC Wainwright Has Positive Estimate for KALA BIO Q3 EarningsAugust 17, 2025 | marketbeat.comWall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to TradeAugust 13, 2025 | zacks.comKALA BIO, Inc.: KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 8, 2025 | finanznachrichten.deKala Bio (KALA) Q2 Loss Widens 15%August 8, 2025 | aol.comAKALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 8, 2025 | globenewswire.comKALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comAnalyst Coverage Sparks Interest in These 4 Stocks Amid VolatilityJuly 25, 2025 | zacks.comKALA Bio completes enrollment of CHASE clinical trialJuly 12, 2025 | ophthalmologytimes.comOKALA BIO Announces Completion of Enrollment in CHASE Clinical Trial ...July 11, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBOLD, KALA, EXOZ, and CNTB Company DescriptionsBoundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Connect Biopharma NASDAQ:CNTB$1.56 -0.07 (-4.29%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.01 (+0.96%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.eXoZymes NASDAQ:EXOZ$12.40 0.00 (0.00%) As of 09/11/2025eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.KALA BIO NASDAQ:KALA$18.62 +1.62 (+9.53%) Closing price 04:00 PM EasternExtended Trading$18.78 +0.16 (+0.86%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
